The Phase 3 IMROZ trial evaluating the investigational use of Sarclisa® in combination with standard-of-care bortezomib, lenalidomide and dexamethasone met its primary endpoint at a planned interim analysis for efficacy, demonstrating statistically significant improvement in progression-free survival compared with VRd alone in transplant-ineligible patients with newly diagnosed multiple myeloma.
